MARKET

XOMA

XOMA

XOMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.50
+0.60
+1.67%
Opening 12:38 02/24 EST
OPEN
35.90
PREV CLOSE
35.90
HIGH
38.35
LOW
35.90
VOLUME
2.09K
TURNOVER
--
52 WEEK HIGH
46.32
52 WEEK LOW
14.14
MARKET CAP
402.29M
P/E (TTM)
-26.1129
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
XOMA to Present at Upcoming Investor Conferences
XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences:
GlobeNewswire · 20h ago
Adrenocorticotropic Hormone Receptor Market Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 -2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 01:37:48 / Comserve Inc. / -- Adrenocorticotropic Hormone Receptor market is segmented by Type, and by Application. Players,...
Comserve · 2d ago
Global Botulism Illness Market Possible Growth Factors 2021-2027 Microbiotix, XOMA Corporation, AlphaVax
Market Insight Reports · 01/28 07:41
Botulinum Market Size 2021 Research Report with Manufactures, Product Types, End-Users, Opportunities, Strategies, Covid-19 Impact and Forecast to 2025
Jan 25, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Botulinum Market” Report 2021 - 2025...
The Express Wire · 01/25 06:58
Botulism Illness Market Industry Analysis, Key Player profile, Size, Share, Growth, Trends, and Regional Outlook by 2027
Jan 13, 2021 (Heraldkeepers) -- Global & US Botulism Illness Market by Drug types (antibiotics, antitoxins & others (trivalent & heptavalent) and by...
Heraldkeepers · 01/13 09:11
XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences
XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:
GlobeNewswire · 01/04 21:05
XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences
XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:
GlobeNewswire · 01/04 21:05
XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences
EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: * H.C. Wainwright Virtual BioConnect 2021 Conference taking p...
GlobeNewswire · 01/04 21:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XOMA. Analyze the recent business situations of XOMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XOMA stock price target is 46.00 with a high estimate of 56.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 6.93M
% Owned: 62.90%
Shares Outstanding: 11.02M
TypeInstitutionsShares
Increased
18
215.32K
New
17
10.33K
Decreased
11
106.24K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.66%
Pharmaceuticals & Medical Research
+1.41%
Key Executives
Chairman/Independent Director
W. Denman Van Ness
Chief Executive Officer/Director
James Neal
Chief Financial Officer/Senior Vice President
Thomas Burns
Chief Financial Officer/Vice President - Finance
William Garrard
Director
Natasha Hernday
Independent Director
Barbara Kosacz
Independent Director
Joseph Limber
Independent Director
Matthew Perry
Independent Director
Jack Wyszomierski
  • Dividends
  • Splits
  • Insider Activity
No Data
About XOMA
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Webull offers kinds of XOMA Corp stock information, including NASDAQ:XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.